首页> 外文期刊>Intelligence: A Multidisciplinary Journal >CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane

【24h】

CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane

机译：Contessa 2：跨国，多中心，第2阶段的胸膜蛋白加上患有以前没有接受紫杉烷的人的患者患者的Capecitabine

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
中文文献
专利

1. CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Contessa 2：跨国，多中心，第2阶段的胸膜蛋白加上患有以前没有接受紫杉烷的人的患者患者的Capecitabine
2. CONTESSA TRIO: A multinational, multicenter, phase 2 study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with HER2-metastatic breast cancer (MBC) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Contessa Trio：跨国，多中心，第2期替补患者3种不同的PD-（L）1抑制剂在转移性三阴性乳腺癌（TNBC）和老年人患者中患者的胸膜肺癌（MBC）
3. 2101 ORAL Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) progressing after anthracyclines and taxanes: subgroup analysis of patients receiving ixabepilone in the first-line setting [J] . J.Jassem, E.Thomas, H.Gomez, European Journal of Cancer Supplements . 2007,第4期

机译：蒽环类药物和紫杉烷类药物治疗后转移性乳腺癌（MBC）患者中2101口服依沙贝比隆联合卡培他滨的ORAL III期研究：在一线接受ixabepilone的患者的亚组分析
4. Studies on the side effects of high dose Ⅰ-131 therapy on the patients with metastatic thyroid cancers [C] . The First China-Japan-Korea conference of nuclear medicine . 2002

机译：大剂量Ⅰ-131治疗对转移性甲状腺癌患者的副作用研究
5. Utilities of metastatic breast cancer patients treated with taxanes compared to utilities of oncology nurses. [D] . Hauser, Robert Sean. 2001

机译：与肿瘤科护士相比，使用紫杉烷类治疗的转移性乳腺癌患者的效用。
6. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment [O] . Y H Park, H A Jung, M K Choi, 2014

机译：HER3表达和PTEN缺失在接受紫杉烷联合曲妥珠单抗治疗的HER2过表达转移性乳腺癌（MBC）患者中的作用
7. Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro - AGO-B-046 [O] . S Krajnak, T Decker, L Schollenberger, 2021

机译：II期研究对每日口服血上的衡量治疗作为一线化疗，患者先进/转移性HR + / HER2-乳腺癌对内分泌治疗的抗性：VINOFORGRO-AGO-B-046

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号